Intraductal papillary mucinous neoplasm of the pancreas – epidemiology, risk factors, diagnosis, and management

@article{Aronsson2017IntraductalPM,
  title={Intraductal papillary mucinous neoplasm of the pancreas – epidemiology, risk factors, diagnosis, and management},
  author={Linus Aronsson and Roland Andersson and Daniel Ansari},
  journal={Scandinavian Journal of Gastroenterology},
  year={2017},
  volume={52},
  pages={803 - 815}
}
Abstract Intraductal papillary mucinous neoplasm (IPMN) is one of the most common cystic neoplasms of the pancreas. It is a heterogeneous disease and can be divided into ductal types and morphological subtypes. The incidence of IPMN is increasing, likely due to the widespread use of cross-sectional imaging and a growing elderly population. IPMN poses an increasing demand on the health care system. Current guidelines provide indications for surgery and recommendations for surveillance, but… 
[Intraductal papillary mucinous neoplasm of pancreas].
TLDR
Literature review devoted to pancreatic IPMN is presented, the latest guidelines are compared and several histological subtypes determine clinical course and prognosis.
Intraductal papillary mucinous neoplasm of the pancreas: Cytomorphology, imaging, molecular profile, and prognosis
TLDR
This work examines the cytomorphological features, molecular profile, imaging findings, and prognosis of IPMN on fine needle aspiration (FNA) specimens.
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS: RADIOLOGY METHODS IN THE DEFINITION OF TREATMENT TACTICS
TLDR
Evaluating the capabilities of radiology diagnostic methods in assessing IPMN finds that MRI is a priority method for the diagnosis of IPMN, however, in some cases, the involvement of at least two methods of radiological diagnostics allows to establish the nature of the disease and determine the tactics of treatment.
Pancreatic intraductal papillary mucinous neoplasm with sarcomatous transformation. A case report
TLDR
The case of a 72-year-old female with a previously undescribed sarcomatous transformation of a residual IPMN with no evidence of an invasive component suggests that sarcom atous transformation is possible in non-invasive, intraductal pancreatic lesions.
Assessment of Malignancy Potential in Intraductal Papillary Mucinous Neoplasms of the Pancreas on MDCT.
TLDR
According to the ICG in 2012, patients with IPMNs with only one WF have a low risk for malignancy, and the presence of at least two WFs or any HRS suggests malignant IPMNs.
Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype.
TLDR
Initial surveillance seems to be the most cost-effective strategy in the management of low-risk asymptomatic Branch-duct intraductal papillary mucinous neoplasm (BD-IPMN).
Histopathological evaluation of resected intraductal papillary mucinous neoplasmsreveals distinct patterns of invasion in associated carcinomas.
TLDR
A low resection rate of high-risk IPMNs is reported and novel findings describing inv-IPMNs as a less infiltrative phenotype compared with regular PDAC are presented.
Editorial: Management of the Small Asymptomatic Pancreatic Cyst: Somehow Along the Way We Forgot About the Patient
  • C. Wilcox
  • Medicine
    The American Journal of Gastroenterology
  • 2017
TLDR
This retrospective cohort study underscores the importance of patient comorbidity in management algorithm, and these data should prompt subsequent guidelines to factor in such comorbridity.
Adjuvant therapy in invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a systematic review.
TLDR
It is concluded that adjuvant therapy may be beneficial in invasive IPMN, but current data suggest that it should be given selectively based on individual tumor characteristics, and further prospective, randomized studies are warranted.
Intraductal papillary-mucinous carcinoma with portal vein tumor thrombus and multifocal liver metastasis: An autopsy case
TLDR
The case of a 78-year-old male patient with advanced pancreatobiliary type IPMC with portal vein invasion and liver metastasis, who succumbed to the disease following an exacerbation of IPMC 90 days after the initial presentation.
...
1
2
3
...

References

SHOWING 1-10 OF 199 REFERENCES
Intraductal Oncocytic Papillary Neoplasms of the Pancreas.
TLDR
Features of pancreatic IOPNs are reviewed, differential diagnosis of other intraductal lesions in the pancreas is discussed, and there are limited data regarding the clinical behavior and prognosis of IOPs in comparison to other subtypes of IPMN.
International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas
TLDR
Ovarian-type stroma has been proposed as a requisite to distinguish MCN from IPMN, and some other distinct features to characterize IPMN and MCN have been identified, but there remain ambiguities between the two diseases.
Intraductal papillary mucinous neoplasms of the pancreas—a surgical disease
TLDR
Although most IPMNs should be resected by standard oncological procedures (including lymphadenectomy), small Sendai-negative IPMNs can be treated with limited resections, with a particular focus on surgical approaches to this disease.
Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience
TLDR
IPMNs continue to be recognized with increasing frequency and five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma-in situ (CIS).
Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct
TLDR
In this single-center, retrospective analysis, an MPD diameter of 7.2 mm was identified as an optimal cutoff for a prognostic factor for malignant disease in MD or mixed IPMN and the new management algorithm had a higher sensitivity, negative predictive value, and accuracy than the 2012 version of the International Consensus Guidelines.
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study
TLDR
A consensus nomenclature and criteria for classifying variants as distinctive IPMN subtypes including gastric type, intestinal type, pancreatobiliary type, and oncocytic type are defined and can be used for further analyses of the clinicopathological significance of the variations of IPMN.
The incidence of intraductal papillary mucinous tumors of the pancreas(1).
TLDR
The incidence of intraductal papillary mucinous tumors of the pancreas may be higher than previously recognized and Aggressive resection is warranted based on the favorable prognosis of patients without tumor invasion.
Branch-Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: Clinically and Patient-Reported Outcomes
TLDR
Branch duct IPMNs are very slow-growing neoplasms, and they do not affect the QoL of affected patients, according to the 2-year follow-up results.
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes
TLDR
Analysis of these subtypes indicates that the background epithelium plays an equally, if not more, important role in defining the biology and prognosis of invasive IPMNs, and arise from different epithelial subtypes.
Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas.
TLDR
Patients with non-invasive IPMT survive for long periods after surgery, as do many patients with invasive, non-metastatic IPMT, although intraductal proliferation with a mild degree of atypia may be present at the resection margin.
...
1
2
3
4
5
...